Prediction of crizotinib-midazolam interaction using the simcyp population-based simulator: Comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytess

Drug Metabolism and Disposition

Volumn 41, Issue 2, 2013, Pages 343-352

  Mao, Jialin ^a   Johnson, Theodore R ^a   Shen, Zhongzhou ^a   Yamazaki, Shinji ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; CYTOCHROME P450 3A; MIDAZOLAM;

AREA UNDER THE CURVE; ARTICLE; COMPUTER PREDICTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STRUCTURE; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIMULATOR; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

AREA UNDER CURVE; BIOTRANSFORMATION; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HEPATOCYTES; HUMANS; HYDROXYLATION; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MIDAZOLAM; MODELS, BIOLOGICAL; PYRAZOLES; PYRIDINES; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER;

EID: 84872736842     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049114     Document Type: Article

References (35)

1. Boulenc X and Barberan O (2011) Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development. Drug Metabol Drug Interact 26: 147-168.
2. Chen Y, Liu L, Monshouwer M, and Fretland AJ (2011) Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drugdrug interactions. Drug Metab Dispos 39:2085-2092.
3. Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, Silva J, Sinha V, Sinz M, and Skerjanec A (2009) In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective. Drug Metab Dispos 37:1339-1354.
4. Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, and Botrous I, et al. (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54:6342-6363.
5. Di L, Keefer C, Scott DO, Strelevitz TJ, Chang G, Bi YA, Lai Y, Duckworth J, Fenner K, Troutman MD, and Obach RS (2012) Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. Eur J Med Chem. [published ahead of print].
6. Di L, Whitney-Pickett C, and Umland JP, Zhang H, Zhang X, Gebhard DF, Lai Y, Federico 3rd JJ, Davidson RE, Smith R, et al. (2011) Development of a new permeability assay using lowefflux MDCKII cells. J Pharm Sci 100:4974-4985.
7. Ernest CS, 2nd, Hall SD, and Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583-591. (Pubitemid 40189555)
8. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, and Obach RS (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
9. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708.
10. Grimm SW, Einolf HJ, Hall SD,, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, and Skordos KW, et al. (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355-1370.
11. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, and Rostami-Hodjegan A (2009) The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211-223.
12. Johnson TR, Zhou S, Lee C et al. (2011a) Identification of the human enzymes involved in the oxidative metabolism of crizotinib, in 17th North American Regional ISSX Meeting; 2011 Oct 16-20; Atlanta, GA. International Society for the Study of Xenobiotics, Washington, DC.
13. Johnson TR, Goulet L, Smith EB et al. (2011b) Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects, in 17th North American Regional ISSX Meeting; 2011 Oct 16-20; Atlanta, GA. International Society for the Study of Xenobiotics, Washington, DC.
14. Jones HM, Parrott N, Jorga K, and Lavé T (2006) A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511-542.
15. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, and Sugiyama Y (2000) Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 17:419-426. (Pubitemid 30395296)
16. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, and Unadkat JD (2011) Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos 39:1070-1078.
17. Lavé T, Parrott N, Grimm HP, Fleury A, and Reddy M (2007) Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 37: 1295-1310. (Pubitemid 350035528)
18. Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, and Hall SD (2011) Prediction of CYP3Amediated drug-drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos 39:591-602.
19. Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, and Hall SD (2012) Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos 40: 706-716.
20. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28: 1031-1037. (Pubitemid 30660356)
21. Nestorov I (2007) Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3:235-249. (Pubitemid 47321518)
22. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348. (Pubitemid 41832613)
23. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255. (Pubitemid 46148737)
24. Rodgers T, Leahy D, and Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276. (Pubitemid 40904190)
25. Rostami-Hodjegan A and Tucker G (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today 1:441-448. (Pubitemid 40186348)
26. Rowland Yeo K, Walsky RL, Jamei M, Rostami-Hodjegan A, and Tucker GT (2011) Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci 43: 160-173.
27. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
28. Slaughter RL and Edwards DJ (1995) Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 29:619-624.
29. Xu L, Chen Y, Pan Y, Skiles GL, and Shou M (2009) Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metab Dispos 37:2330-2339.
30. Yamazaki S, Skaptason J, Romero D, Vekich S, Jones HM, Tan W, Wilner KD, and Koudriakova T (2011) Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. Drug Metab Dispos 39:383-393.
31. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684. (Pubitemid 47578116)
32. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9: 384-394.
33. Zhao P (2008) The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo. Expert Opin Drug Metab Toxicol 4:151-164. (Pubitemid 351308414)
34. Zhao P, Kunze KL, and Lee CA (2005) Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 33:853-861. (Pubitemid 40686640)
35. Zimmerlin A, Trunzer M, and Faller B (2011) CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab Dispos 39:1039-1046.